Atai Life Sciences N.V. (ATAI)
| Previous Close | 2.0700 |
| Open | 2.0700 |
| Bid | 2.0600 x 600 |
| Ask | 2.1100 x 1200 |
| Day's Range | 2.0500 - 2.1300 |
| 52 Week Range | 1.0250 - 2.8500 |
| Volume | |
| Avg. Volume | 1,633,372 |
| Market Cap | 346.945M |
| Beta (5Y Monthly) | 0.98 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2500 |
| Earnings Date | May 07, 2024 - May 14, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.68 |
Simply Wall St.Atai Life Sciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
Atai Life Sciences ( NASDAQ:ATAI ) Full Year 2023 Results Key Financial Results Net loss: US$40.2m (loss narrowed by...
GlobeNewswireatai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights
Strategic investment in Beckley Psytech to accelerate the development of psychedelic-based therapies that fit within the two hour in-clinic treatment paradigm established by Spravato®Initial BPL-003 (intranasal 5-MeO-DMT) Phase 2a open-label results demonstrated a rapid and durable antidepressant effect through three months in TRD patients; top-line results from a controlled Phase 2b TRD study anticipated in 2H 2024Dosing commenced in VLS-01 (oral transmucosal DMT) Phase 1b study, with optimized
- GlobeNewswire
atai Life Sciences Announces Positive Initial Results from Beckley Psytech’s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression
- A single dose of BPL-003 demonstrated a rapid and durable antidepressant effect in TRD patients, with 45% of patients in clinical remission at week 12 - 55% of patients achieved a clinical response on the day after dosing and this rate of response was maintained at week 4 and week 12 - BPL-003 showed a good safety profile and was well-tolerated with no serious adverse events reported - Acute effects resolved on average in less than two hours, highlighting BPL-003’s potential to fit within the
